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Summary
Objective: To determine if levels of the cartilage-speciﬁc (VCC) ﬁbronectin isoform in the synovial ﬂuid is associated with cartilage change
during osteoarthritis.
Design: Synovial ﬂuid was collected from 26 healthy dogs presenting to the Orthopedic Surgery Clinic with unilateral cranial cruciate rupture,
22 control dogs, and 13 dogs from a colony maintained for the study of canine hip dysplasia. Total ﬁbronectin, (VCC) ﬁbronectin, and
cartilage oligomeric matrix protein (COMP) were quantitated by ELISA assays. Statistical analysis used Wilcoxon’s signed-rank and rank-sum
tests and Spearman’s rank correlation.
Results: The concentration of total ﬁbronectin was increased in affected (P! 0.0001) and contralateral (PZ 0.0005) knees of the clinic
population (compared to unaffected knees in colony controls). Both (VCC) ﬁbronectin and COMP concentrations were elevated in the
contralateral knees in clinical patients relative to unaffected knees in the colony controls (PZ 0.03 and PZ 0.04, respectively), and relative to
the affected knees (PZ 0.003); however, corrections for joint effusions suggest elevated totals in the affected knees. (VCC) ﬁbronectin and
COMP concentrations were correlated (rspZ 0.74; P! 0.0001) in 30 unaffected knees of patients and colony controls. Total ﬁbronectin was
correlated negatively with months since the initial injury (rspZ0.44; PZ 0.03) in the affected joints. The intraoperative lesion severity score
did not correlate with total ﬁbronectin or (VCC) ﬁbronectin (P R 0.35).
Conclusions: Concentration of total ﬁbronectin in synovial ﬂuid might be a useful biomarker for cross-sectional studies in osteoarthritis, but
only (VCC) ﬁbronectin provides information speciﬁcally about cartilage damage. Elevated concentrations of (VCC) ﬁbronectin and
COMP seen in the contralateral knees of patients with cranial cruciate rupture might indicate cartilage changes early in the disease process
( pre-clinical). However, the wide range of values obtained limits the diagnostic value for any one individual. Joint effusions obscure the total
amount of biomarkers in affected synovial joints.
ª 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis is a common and major cause of pain and
disability in human and animal patients. Currently there is
a lack of routine diagnostic methods to detect early
osteoarthritis before radiographic changes have occurred.
Non- or minimally-invasive ways to identify individuals in the
early stages of osteoarthritis, to follow its progression or
determine the severity of disease, and to test the efﬁcacy of
various treatment regimens are needed in both human and
veterinary medicine. In addition to imaging modalities,
products of cartilage matrix degradation or turnover which
appear in the blood, urine or synovial ﬂuid have received
much attention since they could serve as biomarkers
for osteoarthritis. However, while there are differences
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and osteoarthritic populations, the variation among individ-
uals has been large. The extensive overlap of values
between affected and unaffected patients limits their use as
a diagnostic tool for any one individual. Existing biomarkers
have shown more promise in longitudinal studies, especially
when synovial ﬂuid is available1. Another approach is to
use combinations of markers, and this does offer more
discrimination2.
One of the more promising markers to date in both
longitudinal and cross-sectional studies is cartilage oligo-
meric matrix protein (COMP), a pentameric matrix protein in
the thrombospondin family. COMP is located preferentially
in the territorial matrix, but also in the interterritorial matrix of
articular cartilage in adults. Its function is not known, but it
may have a role in chondrogenesis and in the interaction of
the chondrocyte with its surrounding matrix3,4. Overall
signiﬁcant increases in synovial ﬂuid and serum COMP
have been reported in human and canine populations with
osteoarthritis5e7, but variation among individuals remains
high. Furthermore, although COMP is found predominantly
in cartilage, it is also present in ligament, tendon, meniscus,
and synovium3,7e9. Furthermore, it also has been found in
mouse skeletal muscle, heart and placenta10. As such, its
elevation in the blood cannot be considered speciﬁc for
articular cartilage degeneration. Additional and better
biomarkers still need to be found.
Fibronectins are important extracellular molecules
through which cells interact with their surrounding matrix.
The (VCC) ﬁbronectin isoform, which lacks the V, III-15
and I-10 segments, is restricted to cartilage in mammals
and constitutes from 50% to 80% of the total ﬁbronectin
present in articular cartilage11. Preliminary studies show
this isoform to be elevated 10-fold in osteoarthritic cartilage
and its loss appears to be a very early and sensitive marker
of chondrocyte dedifferentiation12e14. A monoclonal anti-
body has been developed that makes it possible to detect
this isoform without cross-recognition of other ﬁbronectin
isoforms present in blood and synovial ﬂuid13. Since
(VCC) ﬁbronectin is speciﬁc to cartilage, its presence in
bodily ﬂuids infers a cartilage origin12. Thus (VCC)
ﬁbronectin could be an excellent biomarker to monitor
cartilage changes during osteoarthritis progression, re-
sponse to therapy, and the quality of cartilage repair. Our
hypothesis is that (VCC) ﬁbronectin in the synovial ﬂuid
will be associated with the presence of osteoarthritis. We
tested this hypothesis in a canine model of spontaneous
osteoarthritis consequent to hip dysplasia, and in dogs
which presented at the Cornell University Hospital for
Animals with rupture of the cranial (anterior) cruciate
ligament (CCL). For comparison, analysis of COMP was
performed on the same samples.
Materials and methods
COLLECTION OF BIOLOGICAL SAMPLES
Clinic dogs
Twenty-six otherwise healthy dogs presenting to the
Orthopedic Surgery Service for surgical stabilization of
naturally occurring, unilateral CCL rupture were included in
this study. Clinical patients exhibiting bilateral CCL rupture,
or other important orthopedic diseases (manifested by
lameness, palpable musculoskeletal abnormality, or pain on
joint manipulation not associated with the CCL rupture)were excluded. The left side was affected in 21 dogs.
Previous therapy included non-steroidal anti-inﬂammatory
drugs (16/26), corticosteroids (3/26) and chondroprotective
agents (6/26). At presentation, dogs had been lame for 2
weeks to 2 years (median, 5 months). For each patient,
lateral and cranio-caudal (antero-posterior) radiographs of
both stiﬂes were obtained preoperatively. Synovial ﬂuid
from both stiﬂes was collected aseptically and percutane-
ously prior to surgical intervention in the affected stiﬂe. The
joint was held in slight ﬂexion and stiﬂe landmarks were
palpated. A 1 and 1/2-inch, 22-gauge needle was inserted
in a cranio-caudal direction at right angles to the joint at
a location just lateral to the patellar tendon and midway
between the patella and the most proximal aspect of the
tibial tuberosity. Synovial ﬂuid was aspirated from the joint
with a 6-cc syringe. Protease inhibitors [0.3 mM benzami-
dene/20 mM ethylenediamine tetraacetic acid (EDTA)/
10 mM N-ethylmaleimide/0.4 mM phenylmethylsulfonyl ﬂuo-
ride (PMSF), ﬁnal concentrations; pH 7.0] were added to the
synovial ﬂuid at one-tenth the volume. Synovial ﬂuid was
stored at 80(C until the individual assays were performed.
An open arthrotomy was performed on the affected stiﬂe
and the joint was evaluated for gross evidence of
osteoarthritis prior to surgical stabilization.
The breeds of dogs seen as clinical patients included
Labrador Retriever (5), Rottweiler (3), Airdale Terrier (1),
Australian Shepherd (1), Beagle (1), German Shepherd (1),
Golden Retriever (1), Siberian Husky (1), and mixed breed
(12). Of the clinical patients, 12 were castrated males, and
14 were spayed females. The median age for the clinical
patients was 4.5 years (range 2e10 years).
Colony dogs
Synovial ﬂuid was obtained at necropsy from the stiﬂes of
22 laboratory dogs (4 Labrador RetrievereGreyhound
cross-breeds and 18 beagles) that did not exhibit evidence
of clinical lameness or stiﬂe arthropathy. These animals
served as normal controls for the clinic dogs with unilateral
CCL rupture. The beagles were from a colony maintained
for unrelated research at the Cornell College of Veterinary
Medicine. The Labrador RetrievereGreyhound crosses
were from a colony for the study of canine hip dysplasia
and osteoarthritis maintained at the Baker Institute for
Animal Health. Synovial ﬂuid sample volume was noted,
protease inhibitors were added, and samples were frozen at
80(C until further analysis. Of the colony dogs, 8 were
intact males, and 14 were intact females. The median age
was 3 years (range 1e8 years).
An additional four Labrador Retrievers and nine Labrador
RetrievereGreyhound cross-breeds were examined for the
presence of visible cartilage lesions on hips, shoulders or
stiﬂes at necropsy. Dogs with no visible lesions on any joint
were classiﬁed as ‘‘normal.’’ Dogs with a visible cartilage
lesion in a hip joint were classiﬁed as ‘‘dysplastic.’’ A joint
with no cartilage lesion from a dysplastic dog or from a
normal dog was classiﬁed as ‘‘unaffected.’’ Joints with
cartilage lesions were classiﬁed as ‘‘affected.’’ Dogs with
hip lesions often have cartilage lesions in multiple joints15.
Synovial ﬂuid was collected, volume noted, and frozen at
80(C with protease inhibitors. The age at necropsy
ranged from 8 months to 11 years. The median age at
necropsy was 28 months. This project was approved by the
Cornell University Animal Care and Use Committee.
Figure 1 depicts schematically the dog populations used
in this study.
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An aliquot of synovial ﬂuid was placed on gelatin-coated
slides, ﬁxed and stained as previously described16,17. A
piece of synovial membrane was excised from the cranio-
lateral aspect of the stiﬂe joint and ﬁxed in 10% formalin.
Microscopic examination determined the inﬁltration and
distribution of inﬂammatory cells, the presence of synovial
hyperplasia, and the morphology of synovial lining cells. All
cytologic and histopathologic preparations were evaluated,
blinded, by one author (Freeman).
QUANTITATION OF FIBRONECTINS AND COMP BY ELISA
Fibronectins
Concentration of total ﬁbronectin was quantitated by
ELISA as described previously18. The concentration of
(VCC) ﬁbronectin was quantitated in a sandwich ELISA
using the monoclonal antibody Mab5D10 anti (VCC) as
the capture antibody. The assay, as well as characterization
of the antibody as speciﬁc for (VCC) ﬁbronectin with no
cross-recognition of VC/CC isoforms, has been de-
scribed13. Further modiﬁcations have increased assay
sensitivity. Speciﬁcally, 72 wells of a 96-well NUNC
(Rochester, NY) plate were coated with 1 mg of puriﬁed
Mab5D10 IgG diluted in 10 mM TRIS, pH 9.4 and kept at
37(C for 12e18 h. Wells were then blocked with 4% non-fat
dry milk in 50 mM NaHCO3, pH 8.0. Synovial ﬂuid was
thawed and digested with bovine testicular hyaluronidase
(Calbiochem, La Jolla, CA) at 1 ml of hyaluronidase per
100 ml of ﬂuid (1 unit/ml, ﬁnal concentration) at 37(C for
45 min7. Following hyaluronidase treatment, the synovial
ﬂuid was diluted into 4% milk in 50 mM NaHCO3, pH 8.0
and added to the wells. Plates were incubated at 37(C for
3 h. The primary antibody was rabbit anti-human ﬁbronectin
(Cappel, Durham, NC) diluted 1:1000 into 4% milk in 0.05 M
phosphate buffer, pH 7.0 containing 0.15 M NaCl. Thesecondary antibody was peroxidase-linked mouse anti-
rabbit IgG (Sigma, St. Louis, MO) at a 1:10,000 dilution.
Detection used a Quanta-Blu Kit with ﬂuorogenic peroxi-
dase substrate (Pierce, Rockford, IL) and ﬂuorescence was
read on an ELISA plate reader (Tecan, Saﬁre with Magellan
software; Triangle Research Park, NC). Wells with no
capture antibody and wells with no ﬁrst-stage antibody
served as negative controls.
Cartilage oligomeric matrix protein
Prior to the COMP assay, all synovial ﬂuid samples were
treated with hyaluronidase as described above with in-
cubation at 37(C for 45 min. The concentration of COMP
was quantitated by competitive inhibition ELISA with
monoclonal antibody 17-C10 as previously described, with
minor modiﬁcations6,19. Puriﬁed canine COMP antigen was
used as both a COMP standard and as a plate-coating
antigen in the ELISA. A 96-well NUNC-Immuno plate
(Rochester, NY) was coated with 50 ml of canine COMP
antigen (0.3 mg/ml) in 20 mM sodium carbonate, 20 mM
sodium bicarbonate, 0.0025% sodium azide, pH 10, and
incubated for 2 h at room temperature, and then kept at 4(C
for 12e18 h.
The initial dilution of monoclonal antibody 17-C10 was
1:40,000 in PBS-0.05% Tween 20 (PBS-Tween), 1%
bovine serum albumin (BSA), pH 7.0. Canine COMP
standards were prepared to 0.8 mg/ml, 0.6 mg/ml, 0.4 mg/
ml, 0.3 mg/ml, 0.2 mg/ml, 0.15 mg/ml, 0.1 mg/ml, and
0.075 mg/ml in PBS-Tween, pH 7.0. Synovial ﬂuids were
diluted 1/25, 1/37.5, 1/50, 1/75, 1/100, 1/200, and 1/300 in
the same buffer. COMP standard or unknown synovial ﬂuid
was mixed with the antibody in a NUNC-Microwell plate and
maintained at 4(C for 12e18 h. The plates previously
coated with canine COMP antigen were washed three times
with PBS-Tween and blocked prior to use by incubating for
60 min on an orbital shaker with 100 ml of PBS, 5% BSA, pH
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100 ml of the monoclonal antibody-COMP inhibition mixture
for 2 h at room temperature. The secondary antibody was
peroxidase-linked goat anti-mouse IgG (A4416, Sigma),
diluted 1:5000 in PBS-Tween, 1% BSA, pH 7.0. Detection
was with o-phenylenediamine plus H2O2 and color was
quantitated with an ELISA plate reader (EL340, Bio-Tek
Instruments) using KC junior software (Bio-Tek Instru-
ments).
SCORING SYSTEMS
Radiographic scores
Lateral and cranio-caudal radiographs of the affected and
unaffected stiﬂes were performed on all clinical patients. All
radiographs were evaluated, blinded, by one author
(Nykamp) and each joint was scored separately. Each joint
was evaluated for radiographic evidence of joint effusion,
subchondral sclerosis, subchondral cysts, periarticular
osteophytes, enthesiophytes, intra-articular calciﬁed bod-
ies, and periarticular calciﬁed bodies. Each of these
categories were scored with 0Z absent, 1Zmild, 2Zmo-
derate, 3Z severe. The total of all subscores on the scoring
sheet was considered the radiographic score for a given
joint (range 0e21).
Intraoperative scores
The affected joints of the clinical patients and all joints of
the colony dogs were evaluated via open arthrotomy at
surgery or necropsy, respectively. Each joint was evaluated
for thickening of the joint capsule, ﬁbrillation of the articular
cartilage, enthesiophytes, osteophytes associated with the
patella, and osteophytes on the trochlear ridges. Each of
these categories were scored with 0Z absent, 1Zmild,
2Zmoderate, 3Z severe as described previously20. The
total of all subscores on the scoring sheet was considered
the intraoperative score for a given joint (range 0e15).
STATISTICAL ANALYSIS
Clinic dogs with colony controls
The Wilcoxon signed-rank test was used to make within-
group comparisons (affected vs unaffected joints in clinical
patients) and the Wilcoxon rank-sum test was used to make
between-group comparisons (clinic dogs vs colony dogs).
Within each group, Spearman’s rank test was used to
detect correlations among total ﬁbronectin, (VCC)
ﬁbronectin and COMP. For all tests P! 0.05 (two-tailed)
was considered signiﬁcant.
Colony dogs
For statistical analysis, at most two joints from a dysplastic
dog, one affected and one unaffected, were allowed. From
normal dogs, only one joint, which was unaffected, was
allowed. Since synovial ﬂuid samples from multiple joints in
the same dog had been collected, selection of the joint for
analysis was made following a predetermined sequence of
rules. First, from among affected joints, the one with the
highest necropsy score based on size of lesion and, if a hip
joint, synovial ﬂuid volumes O0.3 ml and round ligament
volumes O0.9 ml were selected. Then, if multiple affected
or unaffected joints per dog still remained, the highest total
ﬁbronectin concentration was the ﬁnal selection criterion.This yielded three groups: (1) affected joint, dysplastic dog,
(2) unaffected joint, dysplastic dog, and (3) unaffected joint,
normal dog, with any single dog represented no more than
once in each group. Wilcoxon’s rank-sum test was used to
test for differences between unaffected joints in normal
dogs and either unaffected or affected joints in dysplastic
(osteoarthritic) dogs. Wilcoxon’s signed-rank test was used
for paired comparisons between affected and unaffected
joints in the dysplastic (osteoarthritic) dogs. Within each
group, Spearman’s rank correlation test was used to detect
correlations among total ﬁbronectin, (VCC) ﬁbronectin,
and COMP. For all tests, P! 0.05 (two-tailed) was
considered signiﬁcant.
Results
TOTAL FIBRONECTIN
The concentration of total ﬁbronectin was increased
signiﬁcantly in synovial ﬂuid from both affected
(P! 0.0001) and contralateral, clinically unaffected
(PZ 0.0005) knees of the clinic population with CCL
deﬁciency relative to unaffected knees of colony control
dogs (Table I). The concentration of total ﬁbronectin
seemed higher by inspection in the synovial ﬂuid in those
joints which had cartilage lesions concomitant with canine
hip dysplasia but this increase was not statistically
signiﬁcant (PZ 0.08) (Table II).
Table I
Fibronectin, (VC C) fibronectin, COMP and fluid volume for
synovial fluid from clinic patients with cranial cruciate ligament
rupture
Clinical
patient
affected stiﬂe
Clinical patient
contralateral
stiﬂe
Colony control
dog unaffected
stiﬂe
Fluid volume (ml) 1450y 160 100
(110e4500)z (0e1500) (0e400)
[26]x [26] [22]
PZ 0.0001k P! 0.0001;
PZ 0.08{
Total ﬁbronectin
(mg/ml)
404 213 99
(253e846) (64e392) (54e139)
[26] [19] [14]
PZ 0.0001 P! 0.0001;
PZ 0.0005
(VCC)
Fibronectin (mg/ml)
9.1 13.6 7.6
(3.5e21) (4.4e29) (3.2e32)
[26] [19] [14]
PZ 0.003 PZ 0.36;
PZ 0.03
COMP (mg/ml) 23 33 25
(17e49) (13e63) (19e45)
[26] [16] [15]
PZ 0.003 PZ 0.49;
PZ 0.04
Synovial ﬂuid was collected and analyzed as described in
Materials and methods.
yMedian.
zMinimumemaximum.
xNumber of dogs.
kTwo-tailed P compared to clinical patient unaffected stiﬂe
(signed-rank test).
{Two-tailed P compared to clinical patient affected and un-
affected stiﬂes, respectively (rank-sum test).
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In the clinic dogs, (VCC) ﬁbronectin and COMP
concentrations were not signiﬁcantly different in synovial
ﬂuid from knees with CCL deﬁciency compared to synovial
ﬂuid from knees of control animals. However, both (VCC)
ﬁbronectin and COMP concentrations were elevated in the
synovial ﬂuid from the contralateral knees in the dogs with
CCL deﬁciency compared to synovial ﬂuid from the control
dogs (PZ 0.03 and PZ 0.04, respectively) and from the
affected knees (PZ 0.003) (Fig. 2 and Table I). Readers
concerned about a Bonferroni-like correction for the multiple
tests in Table I will note that a decision would change only
for the two tests with PZ 0.04 and PZ 0.03. (VCC)
ﬁbronectin exhibited a wide range of values in the clinic
dogs. (VCC) ﬁbronectin and COMP concentrations were
correlated signiﬁcantly in synovial ﬂuid from the control and
contralateral knees (rspZ 0.74; P! 0.0001, nZ 30), but
not from the control and affected knees (rspZ 0.21,
PZ 0.19, nZ 40).
In the dogs from the colony with canine hip dysplasia, the
concentration of the cartilage-speciﬁc (VCC) ﬁbronectin
isoform in the synovial ﬂuid varied as much as 20-fold and
was not signiﬁcantly different among groups (Table II).
COMP values were not signiﬁcantly different between
affected and unaffected joints, although the number of
samples available for COMP analysis was limited. Never-
theless, COMP values and (VCC) ﬁbronectin concen-
trations in the synovial ﬂuid of the unaffected joint from the
dysplastic dogs were signiﬁcantly correlated (rspZ 1.00;
P! 0.01, nZ 4 dogs).
CORRELATIONS WITH CLINICAL MEASURES
The radiographic scores in the CCL deﬁcient knees were
signiﬁcantly greater (P! 0.0001) than in the contralateral
knees (Fig. 3). The intraoperative scores ranged widely
from 3 to 15 (medianZ 7) and were not correlated with the
radiographic score (rspZ 0.38, PZ 0.07) or with either
the concentration of total ﬁbronectin or with (VCC)
Table II
Fibronectin, (VC C) fibronectin, COMP and fluid volume for
synovial fluid from colony dogs for the study of canine hip dysplasia
and spontaneous osteoarthritis
Dysplastic
dog affected
joint
Dysplastic dog
unaffected
joint
Control dog
unaffected
joint
Fluid volume (ml) 250y 300 200
(100e400)z (100e500) (100e250)
[5, 9]x [5, 9] [4]
Total ﬁbronectin
(mg/ml)
106 67 78
(58e304) (28e118) (34e107)
[8, 9] [8, 9] [4]
(VCC) ﬁbronectin
(mg/ml)
9.9 9.9 9.5
(5e28) (2e45) (2e22)
[8, 9] [8, 9] [4]
COMP (mg/ml) 55 37 18.8
(40e58) (24e63) n.d.
[3, 3] [3, 4] [1]
Synovial ﬂuid was collected and analyzed as described in
Materials and methods.
yMedian.
zMinimumemaximum.
xNumber of dogs in each group for the paired and unpaired
comparisons (respectively) for the dysplastic dogs, and for the
unpaired comparison for the normal dog.ﬁbronectin concentrations in the synovial ﬂuid (both
PO 0.35). Total ﬁbronectin concentration, but not (VCC)
ﬁbronectin concentration, was correlated negatively with
months since the initial injury (rspZ0.44; PZ 0.03).
Microscopic examination of synovial membrane and
exfoliated synovial lining cells conﬁrmed slight to marked,
focally extensive synovial hyperplasia and hypertrophy,
inﬁltration of lymphocytes, neutrophils and eosinophils, and
other evidence of active and chronic inﬂammation. There-
fore, it is not surprising that the affected stiﬂe in the clinical
patients was marked by joint effusions and the synovial ﬂuid
volume was signiﬁcantly elevated compared to synovial
ﬂuid volume from knees of control dogs (P! 0.0001).
Some of the contralateral stiﬂes had elevated synovial ﬂuid
volumes as well (Table I). Multiplication of ﬁbronectin and
COMP values in Table I by total synovial ﬂuid volume reveal
that total amounts of these proteins in the affected joint
were greater than in the control and contralateral joints.
Discussion
The concentration of total ﬁbronectin is increased in
cartilage of osteoarthritic hip joints secondary to hip
Fig. 2. COMP and (VCC) ﬁbronectin in synovial ﬂuid in response
to CCL deﬁciency. Synovial ﬂuid samples were collected and
analyzed for COMP (A) and for (VCC) ﬁbronectin (B) as
described in Materials and methods. Although the data show
considerable overlap among individuals (as can be visualized in
these box and whisker plots, indicating medians, 25th and 75th
percentiles) both COMP and (VCC) ﬁbronectin concentrations
were signiﬁcantly elevated in synovial ﬂuid from the contralateral
knees relative to affected knees (PZ 0.003) and to knees from
control dogs (PZ 0.04 and PZ 0.03, respectively). * indicates
possible outliers.
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ﬁbronectin isoform also is elevated in lesioned cartilage of
osteoarthritic hip joints13. Thus, it was our hypothesis that
the appearance of (VCC) ﬁbronectin in the synovial ﬂuid
would be a biomarker for the development of cartilage
lesions. There is precedent for the use of ﬁbronectin
isoforms to serve as a biomarker for the rheumatic
diseases. Bases encoding two type III homologous protein
segments named ‘‘Extra Domain-A’’ (ED-A) and ‘‘Extra
Domain-B’’ (ED-B) can be spliced in or out in their entirety.
The correlation of the concentration of ED-AC ﬁbronectin in
the synovial ﬂuid with the progression of joint destruction in
rheumatoid arthritis was reported by Shiozawa et al.21. ED-
BC ﬁbronectin levels in plasma were reported to be
elevated in patients with spondyloarthropathy and might
be useful in distinguishing this group of patients from those
with rheumatoid arthritis22.
The elevation of the concentration of total ﬁbronectin in
synovial ﬂuid from the affected joints of the clinic patients
was not surprising because an increase in the concentra-
tion of total ﬁbronectin was observed previously in dogs with
osteoarthritis secondary to canine hip dysplasia18. Eleva-
tion in the concentration of total ﬁbronectin also has been
reported in synovial ﬂuid of human patients with osteoar-
thritis23. Failure to reach signiﬁcance for the increased
concentration of total ﬁbronectin in synovial ﬂuid in the hip
dysplasia dogs compared to control dogs in this study was
probably due to limited numbers.
It is interesting to us, however, that the concentration of
total ﬁbronectin was correlated inversely with the duration of
clinical signs in the dogs with knee osteoarthritis, and that
a signiﬁcant elevation also was found in the contralateral
knee without clinically detectable laxity. This suggests that
total ﬁbronectin in synovial ﬂuid is a marker of an early
repair phase post-injury, i.e., an anabolic marker. The
canine clinical patients in our study showed signs of
lameness for a median of 5 months. The radiographic
scores all were less than 8 out of a possible total score of
21, with a median score of 4. Similarly, the median
intraoperative score was 7 out of a possible 15. These
numbers conﬁrm that a mild to moderate form of the
disease, and not end-stage osteoarthritis, was characteris-
tic of this canine clinical population.
Of clinical interest was the signiﬁcant elevation of
(VCC) ﬁbronectin and COMP concentration noted in the
contralateral knee of the clinically affected dogs. In these
knees, (VCC) ﬁbronectin and COMP concentrations also
Fig. 3. Radiographic scores for clinic patients. Lateral and cranio-
caudal radiographs were performed on all clinical patients and
scored as described in Materials and methods. Scores were higher
in the affected stiﬂes in almost all cases; nevertheless, the highest
score was less than 8 out of a possible total of 21.were signiﬁcantly correlated. These contralateral knees
were not yet clinically affected (as judged on physical
examination), but three had mild radiographic evidence of
osteoarthritis. The median radiographic score for these
contralateral knees was 0, but ranged as high as 3. The
signiﬁcant elevation of (VCC) ﬁbronectin and COMP
concentration in these knees suggests that the contralateral
knees are not normal on a population basis; however, they
were not unstable as detected by the anterior cruciate
drawer test which evaluates cranialecaudal (anteriorepos-
terior) instability. The pathogenesis of CCL rupture in the
canine knee has been the subject of debate. Does the
ligament rupture precede the development of osteoarthritis?
Or is there prior osteoarthritis that subsequently results in
ligamentous degeneration and secondary rupture? Indeed,
it is known that knees contralateral to the osteoarthritic knee
are at higher-than-usual risk for CCL tears24. Our data in the
contralateral knee suggest that, prior to palpable effusion,
and prior to any evidence of ligament rupture, (VCC)
ﬁbronectin and COMP concentration might be a marker of
early articular cartilage injury and degeneration. Their
elevation supports the concept of an anabolic response of
the chondrocyte in the early phase of osteoarthritis25,26.
However, longitudinal studies would be required to prove
that this early anabolic phase would lead invariably to
a subsequent catabolic phase.
It is perhaps surprising that no signiﬁcant difference was
found between (VCC) ﬁbronectin concentration in
synovial ﬂuid from the affected joint of the clinical patients
and from the knee joints of the colony dogs which served as
normal controls. However, effusion can affect the concen-
tration of a marker in synovial ﬂuid. Investigators have
attempted to deal with this problem in acute joint injury by
normalizing to the urea concentration expected in a normal
joint27. Because there is a linear relationship between the
concentration of urea in serum and in synovial ﬂuid of
disease-free joints, a normalization factor can be calculated
to account for the dilutional effect of lavage, if lavage is
used to collect synovial ﬂuid. Kraus et al.27 also used this
method to correct for a chymopapain-induced joint effusion.
However, in joints with chronic effusions, urea concen-
trations may not differ from serum concentrations because
urea rapidly equilibrates across the synovium.
Another factor that affects the interpretation of synovial
ﬂuid concentrations of proteins is the clearance rate of
synovial ﬂuid by drainage into the lymphatics. If the
clearance rate stays the same, the synovial ﬂuid volume
is irrelevant to the concentration. However, this is not likely.
There are some reports of signiﬁcant increases in lymphatic
clearance rates in osteoarthritic cartilage in human knees
and in dogs with mild synovitis28,29. Recently, Myers et al.30
measured clearance in dogs prior to and 16 and 32 weeks
after anterior cruciate ligament transection (ACLT) and
documented, on average, a three-fold increase. Prior to
correction for clearance, synovial ﬂuid GAG concentrations
showed no signiﬁcant increase 16 weeks after surgery
(20G 6 mg/ml vs 18G 4 mg/ml). After correction, GAG
concentration in the ACLT knee was raised to 57G 36 mg/
ml. Since we did not measure clearance rate, we cannot be
sure, but we think it likely that concentrations of (VCC)
ﬁbronectin and COMP in the synovial ﬂuid from the affected
knee are underestimated.
Our results with COMP are consistent with those of Vilim
et al.31 who reported signiﬁcantly lower COMP concen-
trations in synovial ﬂuid from knees of human patients with
osteoarthritis and rheumatoid arthritis compared to knees of
normal volunteers. The authors point to the 10-fold
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possible explanation.
Dilutional effects on biomarker concentrations in effusive
joints would not be a problem for useful biomarkers in
serum or plasma. However, the search for combinations of
serum biomarkers to assist in the early diagnosis of
osteoarthritis and to monitor therapy response and pro-
gression has been difﬁcult32e34 especially in cross-section-
al studies35. Further, ethnicity and sex affect serum
concentrations of COMP in humans36. (VCC) ﬁbronectin
is present in plasma at concentrations that are 20-fold or
more less than in synovial ﬂuid, but are quantiﬁable. Work is
in progress to assess the potential of (VCC) ﬁbronectin
as a plasma biomarker.
In contrast to the recent report by Vilim et al.31, COMP
concentrations have been reported as elevated in the
synovial ﬂuid and serum of both human and canine patients
with osteoarthritis2,6,7. COMP generally has been consid-
ered a marker of articular cartilage catabolism, but elevated
levels in synovial ﬂuid or serum could indicate elevated
synthesis and lack of retention in the matrix35. As with other
cross-sectional studies, in our study, there was much
overlap in the ranges of values from control and osteoar-
thritic populations. Similar to the data obtained for (VCC)
ﬁbronectin in the synovial ﬂuid, only the contralateral joint of
the clinic patients showed a statistically signiﬁcant increase.
Because of the categorization of COMP as a catabolic
biomarker, and the presumed anabolic nature of ﬁbronectin
(increased ﬁbronectin in osteoarthritis cartilage results from
both increased synthesis and increased retention18) and
(VCC) ﬁbronectin, the hypothesis was tested that the
combination of the two might prove better at distinguishing
osteoarthritis in hip and stiﬂe joints in a cross-sectional
study than either biomarker alone. However, logistic
regression modeling (data not shown) failed to demonstrate
additional discriminatory power with the addition of COMP
to (VCC) ﬁbronectin concentrations and total ﬁbronectin
concentrations in synovial ﬂuid. In fact, this failure to
demonstrate additional discriminatory power is consistent
with the ﬁnding that (VCC) ﬁbronectin and COMP
concentrations in synovial ﬂuid were signiﬁcantly correlated
in clinical patients and in colony dogs with spontaneous
osteoarthritis. The strong correlation of (VCC) ﬁbronectin
and COMP concentrations suggests that both markers
measure a similar cartilage response process, whether
anabolic or catabolic.
In summary, the elevated concentrations of total ﬁbro-
nectin, (VCC) ﬁbronectin and COMP seen in the
contralateral knees of unilaterally affected dogs with CCL
deﬁciency might be indicative of cartilage changes early in
the disease process ( pre-clinical). Indeed, the contralateral
knees in dogs with CCL deﬁciency are at high risk to
become affected. However, the wide range of values
obtained in these cross-sectional studies would limit the
diagnostic value for any one individual. Others have also
noted that the contralateral joint is not unaffected. Dahlberg
et al.37 reported elevations in COMP fragments in the
contralateral knee in human patients after an unilateral knee
injury. Although the synovial ﬂuid concentrations of
(VCC) ﬁbronectin and COMP were not increased in the
affected knee of dogs with CCL deﬁciency, the large
effusions in those knees probably obscured the fact that
much more (VCC) ﬁbronectin and COMP were released
into the affected joints than into the control joints. Thus, the
ability to monitor cartilage changes by following the
appearance of cartilage matrix components in the synovial
ﬂuid might be masked by inﬂammatory and other changeswithin the joint. Consistent with this, increases in total
ﬁbronectin concentration in synovial ﬂuid from affected
joints in both colony and clinic dogs exceeded changes in
cartilage-speciﬁc (VCC) ﬁbronectin concentration and
may be derived, in part, from non-cartilage sources such as
plasma and synovium. Total ﬁbronectin should be an easy-
to-assay synovial ﬂuid marker to add to biomarker panels
for cross-sectional studies in osteoarthritis. (VCC)
ﬁbronectin can provide information speciﬁcally related to
cartilage damage. However, this study points out that even
for a cartilage-speciﬁc marker like (VCC) ﬁbronectin,
synovial ﬂuid concentrations may not reﬂect the severity of
cartilage degeneration during osteoarthritis.
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